

TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs

<https://marketpublishers.com/r/TD5E7669196EN.html>

Date: August 2016

Pages: 388

Price: US\$ 2,626.00 (Single User License)

ID: TD5E7669196EN

Abstracts

TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016:

Convergence of technologies opens business opportunities beyond CD19 CARTs

The report TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs“ describes and analyzes the status of the adoptive cell therapy industry as of August 2016. The report covers autologous and allogeneic engineered chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapy candidates as well as natural killer (NK) cell and CAR engineered NK cells in research and development by biopharmaceutical companies. Cytotoxic lymphocytes (CTLs), donor lymphocyte infusions (TILs) and tumor infiltrating lymphocytes (TILs) complement the spectrum of the report.

The report highlights and discusses

- Company financing;

- Business development & financing;

- Improvements of CAR T-cell therapy incl. gene editing and universal CARTs;

- Engineered TCR T-cells, including TCR target discovery;

- The current status of DLIs, CTLs and TILs;

Manufacturing of T-cells for adoptive cell therapy;

NK cells and CAR engineered NK cells;

International perspective on TCR & CAR T-cell and NK cell therapy; and

Key success factors & convergence of technologies.

The early and impressive clinical results of anti-CD19 CAR T-cell therapy most probably will see confirmation in ongoing pivotal studies in acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) leading to approval as early as 2017. Supported by Big Pharma money and billions of US\$ by private financing rounds, public offerings and partnering money, Novartis, Juno Therapeutics and Kite Pharma are in a close race to be first on market with autologous CD19 CAR T-cell products. Cash-rich Juno and Kite went on a shopping and licensing tour to add numerous technologies like pearls on a string to be prepared for next generation development candidates.

However, clinical experience with CD19 CAR T-cells and other CAR T-cells for hematologic and solid tumors has revealed quite a number of hurdles. Part of them have to be addressed by protocol issues, such as the pre-conditioning chemotherapy problem, or clinical combination studies with checkpoint inhibitors to modulate the tumor micro-environment. But technological solutions are far more required to improve safety and efficacy as well as convenience and manufacturing of CAR T-cell therapies. Another big issue is the lack of strictly tumor-specific targets.

Among the key technologies are gene editing and TCR target discovery. Companies with such capabilities will have a strong position in financing, partnering and corporate development. This report describes the key players in the field and companies with complementary technologies ideal for joint ventures, or better, mergers.

The analytical evaluation in this report is based on retrieval of information about and detailed description of the profiles of 67 companies and 67 cell therapy product candidates. Information was obtained from 193 scientific references (abstracts, full papers, reviews), press releases, financial information, annual reports, presentations and webcasts. All information sources are fully referenced, either as scientific references or by hyperlinks embedded on the source description for online access to the source.

Who will benefit from this report?

Technology Officers

Corporate Development

Strategic Planning

Business Development & Licensing

Corporate Finance

Portfolio Management

Investors & Analysts

Clinical Development

Research & Development

Contents

1 Executive Summary

2 INTRODUCTION

3 COMPANY FINANCING

3.1 Stock Market

3.2 Partnering Deals

3.3 Early Stage Financing (VC, PE & Other Seed Money)

3.4 Summary & Conclusions

4 BUSINESS DEVELOPMENT & LICENSING

4.1 „Public-Private Partnerships“ between Academia and Industry

4.2 Corporate Alliances & Out-Licensing to Major Pharma & Biotech

4.3 In-Licensing from Pharma & Biotech

4.4 Collaborations & Joint Ventures

4.5 Corporate & Asset Acquisitions

5 IMPROVEMENT OF CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY

5.1 Improvement of Safety

5.1.1 Role of pre-conditioning regimen

5.1.2 Suicide genes as safety switch

5.1.3 Elimination genes as safety switches

5.1.4 Activation genes as safety switches

5.1.5 Safety knock-out

5.1.6 Tumor-specific activation

5.1.7 Prodrug approach

5.1.8 Safer T-cell signaling & activation

5.1.9 Transient CAR expression

5.1.10 Target selectivity & intratumoral delivery

5.2 Gene Editing

5.3 Improvement of Efficacy

5.3.1 T-cell subsets

5.3.2 Genetic modification of T-cells

5.3.3 T-Cell activation & expansion

- 5.3.4 CAR design: antigen-binding domain
- 5.3.5 CAR design: linker/spacer and transmembrane domain
- 5.3.6 CAR design: intracellular signaling domains
- 5.3.7 CAR design: armored CARs against tumor microenvironment
- 5.3.8 Immune checkpoint inhibition
- 5.3.9 T-cell auto-antigen knock-out
- 5.3.10 Target heterogeneity & target loss
- 5.4 Universal CAR T-Cells
- 5.5 Allogeneic CAR T-cells

6 COMPETITIVE CAR T-CELL PIPELINE ANALYSIS

- 6.1 CD19 CAR T-Cells
- 6.2 CD19 CART Pivotal Studies
- 6.3 CD19 CART Developments by Chinese Companies
- 6.4 Further CAR T-Cells against Hematologic Malignancies
- 6.5 CAR T-Cells against Solid Tumors
- 6.6 CAR T-Cell Developments in China
- 6.7 Access to CAR Targets & CAR Target Discovery

7 ENGINEERED TCR T-CELLS

- 7.1 TCR T-Cell Pipeline
- 7.2 TCR Target Discovery
 - 7.2.1 SPEAR T-Cell Technology
 - 7.2.2 Naturally Selected TCRs (BioNTech)
 - 7.2.3 XPRESIDENT
 - 7.2.4 TCR-GENErator
 - 7.2.5 Single-Cell Sequencing (Juno)
 - 7.2.6 Natural, High Affinity TCRs (Bellicum)
 - 7.2.7 Sleeping Beauty Electroporation of TCRs
 - 7.2.8 Combinatorial T Cell Receptor Exchange (CTE)
 - 7.2.9 Tumor-Specific TCR Library (Medigene)
 - 7.2.10 Phagemers (Nextera)
 - 7.2.11 ALPHA Phage Display (Eureka)
 - 7.2.12 Epitarget (AIT)

8 DONOR LYMPHOCYTE INFUSIONS (DLI)

9 CYTOTOXIC T-LYMPHOCYTES (CTL)

10 TUMOR INFILTRATING LYMPHOCYTES (TIL)

11 MANUFACTURING OF T-CELLS FOR ADOPTIVE CELL THERAPY

11.1 In-House Manufacturing

11.2 Manufacturing Time

12 NATURAL KILLER (NK) CELLS

13 INTERNATIONAL PERSPECTIVE ON TCR & CAR T-CELL THERAPY

14 KEY SUCCESS FACTORS & CONVERGENCE OF TECHNOLOGIES

15 COMPANY PROFILES

15.1 Major pharma & biotech companies

15.1.1 Amgen

15.1.2 Celgene

15.1.3 Eli Lilly

15.1.4 GlaxoSmithKline

15.1.5 Janssen

15.1.6 Merck KGaA

15.1.6 Novartis

15.1.7 ONO Pharmaceutical Co

15.1.8 Pfizer

15.1.9 Servier

15.1.10 Shire (Baxalta)

15.2 USA & Canada: technology and development companies

15.2.1 Atara Biotherapeutics

15.2.2 Aurora Biopharma

15.2.3 Bellicum Pharmaceuticals

15.2.4 Bluebird bio

15.2.5 CytomX Therapeutics

15.2.6 Eureka Therapeutics

15.2.7 Formula Pharmaceuticals

15.2.8 iCell Gene Therapeutics

15.2.9 Intrexon

- 15.2.10 Juno Therapeutics
- 15.2.11 Kite Pharma
- 15.2.12 Lion Biotechnologies
- 15.2.13 MaxCyte
- 15.2.14 Mustang Bio
- 15.2.15 Nantkwest
- 15.2.16 Poseida Therapeutics
- 15.2.17 Precision BioSciences
- 15.2.18 Sorrento Therapeutics
- 15.2.19 TNK Therapeutics
- 15.2.20 Triumvira Immunologics
- 15.2.21 Unum Therapeutics
- 15.2.22 Vor Biopharma
- 15.2.23 ZIOPHARM Oncology

15.3 Europe: technology & development companies

United Kingdom:

- 15.3.1 Adaptimmune Therapeutics
- 15.3.2 Autolus
- 15.3.3 Catapult Therapy TCR
- 15.3.4 Cell Medica
- 15.3.5 Chimeric Therapeutics
- 15.3.6 Leucid Bio
- 15.3.7 Oxford BioMedica
- 15.3.8 The Cell & Gene Therapy Catapult

France, Belgium & Italy

- 15.3.9 Cellectis
- 15.3.10 Celyad
- 15.3.11 MolMed
- 15.3.12 Theravectys

Germany

- 15.3.13 BioNTech
- 15.3.14 CPT - Cellex Patient Treatment & GEMoaB Monoclonals
- 15.3.15 Immatix
- 15.3.16 Medigene
- 15.3.17 Miltenyi Biotec

The Netherlands, Norway & Finland

- 15.3.18 Gadeta
- 15.3.19 Nextera
- 15.3.20 TILT Biotherapeutics

15.4 Asia

Japan & Korea

15.4.1 Green Cross Lab Cell

15.4.2 Takara Bio

China

15.4.3 American Yuva Biomed

15.4.4 Beijing Doing Biomedical

15.4.5 CARsgen Therapeutics

15.4.6 Cellular Biomedicine Group

15.4.7 Immune Therapeutics

15.4.8 Innovative Cellular Therapeutics

15.4.9 JW Biotechnology

15.4.10 PersonGen BioTherapeutics

15.4.11 Shanghai GeneChem

15.4.12 Shenyang Sunshine Pharmaceutical

15.4.13 Sinobioway Cell Therapy

16 CELL THERAPY PROFILES

16.1 CD19-targeted CAR T-cell therapeutics:

16.1.1 4SCAR19

16.1.2 BPX-401

16.1.3 CBM-CD19.1

16.1.4 CD19 CAR T-Cells (1st generation ZIOPHARM)

16.1.5 CD19 CAR T-Cells (2nd generation ZIOPHARM)

16.1.6 CTL019

16.1.7 CTL119

16.1.8 Fully human anti-CD19 CAR T (NCI & Kite)

16.1.9 JCAR014

16.1.10 JCAR015

16.1.11 JCAR017

16.1.12 KTE-C19

16.1.13 UCART19

16.2 CD123-targeted CAR T-cell therapeutics:

16.2.1 CART123

16.2.2 MB-102

16.2.3 UCART123

16.3 BCMA-targeted CAR T-cell therapeutics:

16.3.1 bb2121

16.3.2 CART-BCMA

16.4 Fc-targeted CAR T-cell therapeutics:

16.4.1 ACTR087

16.4.2 ATTCK20

16.5 IL-13R α 2-targeted CAR T-cell therapeutics:

16.5.1 Anti-IL-13R α 2 IgCD28TCR

16.5.2 MB-101

16.6 Other solid tumor-targeted CAR T-cell therapeutics:

16.6.1 Anti-CEA IgCD28TCR

16.6.2 Anti-c-Kit IgCD28TCR

16.6.3 Anti-GD3 IgCD28TCR

16.6.4 Anti-PSMA IgCD28TCR

16.6.5 AU105

16.6.6 BPX-601

16.6.7 CART-EGFRVIII

16.6.8 CBM-EGFR.1

16.6.9 CSG-GPC3

16.6.10 JCAR020

16.6.11 JCAR023

16.6.12 JCAR024

16.6.13 OXB-302

16.7 Other hematologic malignancy-targeted CAR T-cell therapeutics:

16.7.1 CAR-CD44v6

16.7.2 CBM-CD20.1

16.7.3 CBM-CD30.1

16.7.4 CD33 CAR

16.7.5 JCAR018

16.7.6 NKR-2

16.7.7 UCART38

16.7.8 UCARTCS1

16.8 MAGE (A3 / A4 / A10)-targeted TCR T-cell therapeutics:

16.8.1 MAGE A3 TCR (NCI & Kite)

16.8.2 MAGE A10c796 TCR

16.8.3 TB-1201

16.9 Alpha-Fetoprotein-targeted TCR & TCR-like T-cell therapeutics

16.9.1 AFP-TCR

16.9.2 ET1402L1

16.10 NY-ESO-1-targeted TCR T-cell therapeutics

16.10.1 NY-ESOc259; GSK9377794

- 16.10.2 TB-1301
- 16.11 WT1-targeted TCR T-cell therapeutics
 - 16.11.1 Autologous WT1 TCR
 - 16.11.2 JTCR016
- 16.12 TCR T-cell therapeutics against other targets
 - 16.12.1 BPX-701
 - 16.12.2 TEG
- 16.13 Cytotoxic T Lymphocyte (CTL) therapeutics
 - 16.13.1 CMD-003; baltaleucel-T
 - 16.13.2 CMV-CTL
 - 16.13.3 Cytovir
 - 16.13.4 EBV-CTL
 - 16.13.5 WT1-CTL
- 16.14 Donor Lymphocyte Infusion (DLI) therapeutics
 - 16.14.1 BPX-501
 - 16.14.2 Zalmoxis
- 16.15 Tumor Infiltrating Lymphocyte (TIL) therapeutics
 - 16.15.1 LN-144
 - 16.15.2 LN-145
- 16.16 Natural Killer (NK) cell therapeutics
 - 16.16.1 aNK; Neukoplast; NK-92
 - 16.16.2 haNK; CD16-Neukoplast
 - 16.16.3 Her2.taNK
 - 16.16.4 MG4101

17 REFERENCES

I would like to order

Product name: TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs

Product link: <https://marketpublishers.com/r/TD5E7669196EN.html>

Price: US\$ 2,626.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TD5E7669196EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

